$22.30
-1.07 (-4.58%)
Open$23.48
Previous Close$23.37
Day High$24.08
Day Low$21.00
52W High$44.60
52W Low$6.11
Volume—
Avg Volume678.4K
Market Cap1.35B
P/E Ratio—
EPS$-12.67
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+32.3% upside
Current
$22.30
$22.30
Target
$29.51
$29.51
$22.12
$29.51 avg
$35.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 19.63M | 140.52M | 130.81M |
| Net Income | -616,460,923 | -116,113 | -126,311 |
| Profit Margin | -3,139.8% | -0.1% | -0.1% |
| EBITDA | -614,237,435 | -178,287 | -168,053 |
| Free Cash Flow | — | -139,366 | -118,293 |
| Rev Growth | — | -3.7% | +16.0% |
| Debt/Equity | — | 0.89 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |